MedDRA preferred term · reduced hearing

Hypoacusis: adverse event reports recording this term

42,347 reports to FDA record it, 2004–2026; 0.2% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

42,347
reports recording the term: 0.2% of all reports; 2,644
reports, 12 months to June 2026: 2,818 in the 12 months before; 48.7%
marked serious by the reporter: 57.4% across all reports; 2%
record death among outcomes, as reported: 9.1% across all reports

42,347 reports in FDA's adverse event database record the MedDRA term "Hypoacusis" (in plain words, reduced hearing): 0.2% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

2,644 reports recorded it in the 12 months to June 2026, close to the 2,818 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 48.7% are marked serious, 2% include death among the outcomes and 14.5% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Entresto, Xeljanz and Enbrel. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Entresto	Angiotensin 2 receptor blocker	2,328	2.2%
Xeljanz	Janus kinase inhibitor	1,550	1%
Enbrel	Tumor necrosis factor blocker	1,266	0.2%
Lyrica	—	1,196	1%
Humira	—	1,027	0.2%
Humalog	Insulin analog	925	1.3%
Revlimid	Thalidomide analog	910	0.3%
Ibrance	Kinase inhibitor	881	1.1%
Lantus Solostar	Insulin analog	786	1.7%
Repatha	PCSK9 inhibitor	769	0.5%
Apixaban	Factor Xa inhibitor	676	1.5%
Cosentyx	Interleukin-17A antagonist	625	0.4%
Eliquis	Factor Xa inhibitor	621	0.5%
Forteo	Parathyroid hormone analog	473	0.5%
Tepezza	—	467	8.6%
Trulicity	GLP-1 receptor agonist	445	0.6%
Avonex	Interferon beta	439	0.4%
Insulin glargine	Insulin analog	429	1.5%
Tiotropium bromide	Anticholinergic	396	0.5%
Dupixent	Interleukin-4 receptor alpha antagonist	367	0.1%
Prednisone	Corticosteroid	364	0.2%
Nexium	Proton pump inhibitor	355	0.4%
Tecfidera	—	354	0.3%
Symbicort	Corticosteroid	331	0.8%
Acetaminophen Hydrocodone Bitartrate	—	310	1.1%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.2% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Insulin analog	3,277	1.1%	0.6%
Angiotensin 2 receptor blocker	2,776	1.1%	0.1%
Kinase inhibitor	2,721	0.3%	0.1%
Janus kinase inhibitor	1,869	0.6%	0.2%
Tumor necrosis factor blocker	1,592	0.1%	0.1%
Factor Xa inhibitor	1,511	0.5%	0.1%
Opioid agonist	1,469	0.2%	0.1%
Corticosteroid	1,443	0.2%	0%
Thalidomide analog	1,228	0.2%	0.2%
GLP-1 receptor agonist	1,182	0.3%	0.2%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.2%88

2 to 110.4%183

12 to 170.3%125

18 to 444.1%1,729

45 to 6411.5%4,885

65 to 7413.5%5,699

75 and over22.8%9,663

Age not given47.2%19,975

Patient sex

Female51.9%21,994

Male41.5%17,589

Not given6.5%2,764

Grey bar: all 20,646,523 reports in the database. 82.4% of these reports give the United States as the country.

Questions about "Hypoacusis"

What does "Hypoacusis" mean in an adverse event report?

In plain language: reduced hearing. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record hypoacusis?

42,347 reports through June 2026 (0.2% of all reports), 2,644 of them in the latest 12 months.

Which drugs appear most often in these reports?

Entresto (2,328), Xeljanz (1,550), Enbrel (1,266), Lyrica (1,196) and Humira (1,027). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.